In the context of the move by pharmaceutical companies to develop single enantiomers as drug candidates, researchers from companies and a few universities in Europe, North America, and Australia highlight the problems associated with producing chiral compounds at a commercial scale. They survey the major classes of natural products and describe an array of techniques. No date is noted for the first volume; all the chapters have been updated, and new chapters added for the second.